Norman Klein
Allergy & Immunology · Brooklyn, NYNPI 1184668220
Payments from drug & device makers
Across 105 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1K
- Kaleo, Inc.$216
- Biocryst US Sales Co., LLC$175
- Alk-abello, Inc$171
- Genentech USA, Inc.$159
- Sanofi$124
- plus $491 from 9 others
What the payments were for
- Food & beverage$2,494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 45 | $1,159 |
| Kaleo, Inc. | 9 | $216 |
| Biocryst US Sales Co., LLC | 8 | $175 |
| Alk-abello, Inc | 10 | $171 |
| Genentech USA, Inc. | 7 | $159 |
| Sanofi | 5 | $124 |
| Novartis | 3 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| GSK | 3 | $72 |
| AstraZeneca | 3 | $62 |
| Pfizer | 2 | $46 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 2 | $42 |
| Grifols USA, LLC | 2 | $40 |
| Incyte Corporation | 1 | $25 |
How this compares
$2,494 in reported general payments places this provider in the 45th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 24 | $86,080 |
| XolairOmalizumab | 14 | $37,013 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,710 |
| SingulairMontelukast Sodium | 11 | $2,699 |
| Epinephrine | 11 | $2,208 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $1,065 |
| Fluocinonide | 11 | $980 |
| Azelastine Hcl | 43 | $847 |
| Fluticasone Propionate | 44 | $543 |
| Ipratropium Bromide | 11 | $466 |
| Betamethasone Dipropionate | 11 | $361 |
| Montelukast Sodium | 25 | $323 |
| Doxycycline Hyclate | 22 | $311 |
| Levocetirizine Dihydrochloride | 17 | $141 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Brooklyn
- Payel GuptaBrooklyn$256K
- Bernard SilvermanBrooklyn$174K
- Rauno JoksBrooklyn$171K
- Jenny ShliozbergBrooklyn$164K
- Gad AvshalomovBrooklyn$45K
- Dina LibermanBrooklyn$34K
- Peter DeaneRochester$3.7M
- Syed MustafaRochester$3.6M
- Golda HudesBronx$2.4M
- Arye RubinsteinBronx$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.